172 related articles for article (PubMed ID: 10027779)
1. Peptide binding alpha1alpha2 domain of HLA-B27 contributes to the disease pathogenesis in transgenic mice.
Khare SD; Lee S; Bull MJ; Hanson J; Luthra HS; Hammerling GJ; David CS
Hum Immunol; 1999 Feb; 60(2):116-26. PubMed ID: 10027779
[TBL] [Abstract][Full Text] [Related]
2. Spontaneous inflammatory disease in HLA-B27 transgenic mice is independent of MHC class II molecules: a direct role for B27 heavy chains and not B27-derived peptides.
Khare SD; Bull MJ; Hanson J; Luthra HS; David CS
J Immunol; 1998 Jan; 160(1):101-6. PubMed ID: 9551961
[TBL] [Abstract][Full Text] [Related]
3. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m.
Khare SD; Hansen J; Luthra HS; David CS
J Clin Invest; 1996 Dec; 98(12):2746-55. PubMed ID: 8981920
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mystery of HLA-B27 association with human spondyloarthropathies using transgenic and knock out mice.
Khare SD; Luthra HS; David CS
Semin Immunol; 1998 Feb; 10(1):15-23. PubMed ID: 9529652
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous inflammatory arthritis in HLA-B27 transgenic mice lacking beta 2-microglobulin: a model of human spondyloarthropathies.
Khare SD; Luthra HS; David CS
J Exp Med; 1995 Oct; 182(4):1153-8. PubMed ID: 7561688
[TBL] [Abstract][Full Text] [Related]
6. HLA-B27 transgenic mice are susceptible to collagen-induced arthritis: type II collagen as a potential target in human disease.
Lee S; Khare SD; Griffiths MM; Luthra HS; David CS
Hum Immunol; 2000 Feb; 61(2):140-7. PubMed ID: 10717806
[TBL] [Abstract][Full Text] [Related]
7. Development of spontaneous arthritis in beta2-microglobulin-deficient mice without expression of HLA-B27: association with deficiency of endogenous major histocompatibility complex class I expression.
Kingsbury DJ; Mear JP; Witte DP; Taurog JD; Roopenian DC; Colbert RA
Arthritis Rheum; 2000 Oct; 43(10):2290-6. PubMed ID: 11037889
[TBL] [Abstract][Full Text] [Related]
8. Specificity and frequency of primary anti-HLA cytotoxic T lymphocytes in normal and HLA-B27.2-, HLA-B27.5-, and HLA-Cw3-transgenic mice. A transgenic model for MHC xenoantigen recognition.
Kievits F; Boerenkamp WJ; Lokhorst W; Ivanyi P
J Immunol; 1990 Jun; 144(12):4513-9. PubMed ID: 2351823
[TBL] [Abstract][Full Text] [Related]
9. NK cells from human MHC class I (HLA-B) transgenic mice do not mediate hybrid resistance killing against parental nontransgenic cells.
Kung SK; Su RC; Graham JJ; Chamberlain JW; Miller RG
J Immunol; 1998 Jan; 160(2):674-80. PubMed ID: 9551902
[TBL] [Abstract][Full Text] [Related]
10. Spontaneous inflammatory disease in HLA-B27 transgenic mice does not require transporter of antigenic peptides.
Khare SD; Lee S; Bull MJ; Hanson J; Luthra HS; David CS
Clin Immunol; 2001 Mar; 98(3):364-9. PubMed ID: 11237560
[TBL] [Abstract][Full Text] [Related]
11. Animal models of HLA-B27-associated diseases.
Breban M; Hacquard-Bouder C; Falgarone G
Curr Mol Med; 2004 Feb; 4(1):31-40. PubMed ID: 15011957
[TBL] [Abstract][Full Text] [Related]
12. Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice.
Kuon W; Lauster R; Böttcher U; Koroknay A; Ulbrecht M; Hartmann M; Grolms M; Ugrinovic S; Braun J; Weiss EH; Sieper J
Arthritis Rheum; 1997 May; 40(5):945-54. PubMed ID: 9153558
[TBL] [Abstract][Full Text] [Related]
13. Human MHC class I transgenic mice deficient for H2 class I expression facilitate identification and characterization of new HLA class I-restricted viral T cell epitopes.
Cheuk E; D'Souza C; Hu N; Liu Y; Lang H; Chamberlain JW
J Immunol; 2002 Nov; 169(10):5571-80. PubMed ID: 12421934
[TBL] [Abstract][Full Text] [Related]
14. Animal models of HLA-B27-associated diseases: new outcomes.
Hacquard-Bouder C; Ittah M; Breban M
Joint Bone Spine; 2006 Mar; 73(2):132-8. PubMed ID: 16377230
[TBL] [Abstract][Full Text] [Related]
15. Arthritis in HLA-B27 transgenic animals.
Taurog JD
Am J Med Sci; 1998 Oct; 316(4):250-6. PubMed ID: 9766486
[TBL] [Abstract][Full Text] [Related]
16. HLA class-I-transgenic mice as model system to study MHC-restricted antigen recognition in man.
Weiss EH; Schliesser G; Botteron C; McMichael A; Riethmüller G; Kievits F; Ivanyi P; Brem G
Scand J Rheumatol Suppl; 1990; 87():91-6. PubMed ID: 2259893
[TBL] [Abstract][Full Text] [Related]
17. Rat MHC-linked peptide transporter alleles strongly influence peptide binding by HLA-B27 but not B27-associated inflammatory disease.
Simmons WA; Leong LY; Satumtira N; Butcher GW; Howard JC; Richardson JA; Slaughter CA; Hammer RE; Taurog JD
J Immunol; 1996 Feb; 156(4):1661-7. PubMed ID: 8568273
[TBL] [Abstract][Full Text] [Related]
18. Presentation of HLA class I-derived peptides: potential involvement in allorecognition and HLA-B27-associated arthritis.
Parham P
Immunol Rev; 1996 Dec; 154():137-54. PubMed ID: 9034866
[TBL] [Abstract][Full Text] [Related]
19. Recognition of HLA-B27 by mouse cytotoxic T-cell clones: a transgenic mouse model.
Reboul M; Frangoulis B; Rocca A; Degos L; Pla M
Immunogenetics; 1991; 34(3):196-200. PubMed ID: 1894313
[TBL] [Abstract][Full Text] [Related]
20. In vitro mutagenesis of HLA-B27. Amino acid substitutions at position 67 disrupt anti-B27 monoclonal antibody binding in direct relation to the size of the substituted side chain.
el-Zaatari FA; Sams KC; Taurog JD
J Immunol; 1990 Feb; 144(4):1512-7. PubMed ID: 1689355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
